trial

DAAOI-1 Treatment for Treatment-resistant Schizophrenia

NCTId NCT01390376
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60 (actual)
Sponsored by China Medical University Hospital
Primary completion 2014-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-09
Primary completion
2014-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
DAAOI-1

Sponsors

China Medical University HospitalLead Sponsor
Department of Health, Executive Yuan, R.O.C. (Taiwan)Collaborator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
DAAOI-1 Treatment for Treatment-resistant Schizophrenia — primary completion2014-09

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2
Primary Completion Date
2014-09
Status
COMPLETED
relationships
The graph out of here
drug
DAAOI-1
drug
lead_sponsor
China Medical University Hospital
company
collaborator
Department of Health, Executive Yuan, R.O.C. (Taiwan)
company
indication
Schizophrenia
indication
Schizophrenia
indication